Compare SRPT & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRPT | REAL |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.9B |
| IPO Year | 1997 | 2019 |
| Metric | SRPT | REAL |
|---|---|---|
| Price | $20.46 | $14.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 28 | 8 |
| Target Price | ★ $25.76 | $16.57 |
| AVG Volume (30 Days) | ★ 3.1M | 2.6M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,413,715,000.00 | $662,789,000.00 |
| Revenue This Year | $14.46 | $17.10 |
| Revenue Next Year | N/A | $10.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.15 | 14.30 |
| 52 Week Low | $10.42 | $4.61 |
| 52 Week High | $120.05 | $17.39 |
| Indicator | SRPT | REAL |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 40.34 |
| Support Level | $20.10 | $15.14 |
| Resistance Level | $24.68 | $16.50 |
| Average True Range (ATR) | 1.50 | 0.87 |
| MACD | -0.15 | -0.25 |
| Stochastic Oscillator | 6.99 | 1.80 |
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.